SC 13G: Jasper Therapeutics, Inc.
Ticker: JSPRW · Form: SC 13G · Filed: Mar 27, 2024 · CIK: 1788028
| Field | Detail |
|---|---|
| Company | Jasper Therapeutics, Inc. (JSPRW) |
| Form Type | SC 13G |
| Filed Date | Mar 27, 2024 |
| Risk Level | low |
| Pages | 11 |
| Reading Time | 13 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Jasper Therapeutics, Inc..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G filing submitted by Jasper Therapeutics, Inc. (ticker: JSPRW) to the SEC on Mar 27, 2024.
What is the risk level of this SC 13G filing?
This filing has been assessed as low risk.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ssuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securiti).
How long is this filing?
Jasper Therapeutics, Inc.'s SC 13G filing is 11 pages with approximately 3,212 words. Estimated reading time is 13 minutes.
Where can I view the full SC 13G filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 3,212 words · 13 min read · ~11 pages · Grade level 9.6 · Accepted 2024-03-27 16:26:42
Key Financial Figures
- $0.0001 — ssuer) Voting Common Stock, par value $0.0001 per share (Title of Class of Securiti
Filing Documents
- d11006439_13g.htm (SC 13G) — 219KB
- 0000919574-24-002193.txt ( ) — 221KB
(j) and attach an exhibit stating the identity and Item 3 classification of each member
Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. N/A Item 9. Notice of Dissolution of Group. Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5. N/A Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. March 27, 2024 (Date) David Witzke Avidity Partners Management LP Avidity Partners Management (GP) LLC Avidity Capital Partners Fund (GP) LP Avidity Capital Partners (GP) LLC Avidity Master Fund LP By: /s/ David Witzke David Witzke, for himself and as Managing Member of Avidity Partners Management (GP) LLC (for itself and as general partner of Avidity Partners Management LP) and Avidity Capital Partners (GP) LLC (for itself and as general partner of Avidity Capital Partners Fund (GP) LP (for itself and as general partner of Avidity Master Fund LP)) Michael Gregory Avidity Partners Management LP Avidity Partners Management (GP) LLC Avidity Capital Partners Fund (GP) LP Avidity Capital Part